Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610868 · ClinicalTrials.gov registry record · Phase 3
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
A Phase 3 study of Sialorrhea, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT02610868: Completed Phase 3 study of Sialorrhea, sponsored by Supernus Pharmaceuticals.
NCT02610868 is a Phase 3 study of Sialorrhea that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 187 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02610868, a Phase 3 study of Sialorrhea, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
Primary Outcome
TEAEs Related to Study Medication include TEAEs classified as Possibly, Probably and Definitely Related. Treatment Session (TS)
Conditions Studied
Interventions
- DRUG MYOBLOC
Study Locations (20)
Florida
- - Atlantis
- - Boca Raton
- - Orlando
- - Port Charlotte
Arizona
- - Phoenix
- - Scottsdale
- - Scottsdale
California
- - Loma Linda
- - Los Angeles
Kansas
- - Kansas City
- - Overland Park
Colorado
- - Aurora
Georgia
- - Atlanta
Maryland
- - Elkridge
Michigan
- - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-06 |
| Phase | Phase 3 |
What the finished NCT02610868 record still lists
NCT02610868 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Sialorrhea appearing as the primary indexed condition, and to 1 intervention - of which MYOBLOC is the first listed.
NCT02610868 names 20 study sites across 13 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT02610868 about?
NCT02610868 is a clinical study titled "Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults". Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
What is the current status of trial NCT02610868?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2015-10. Estimated completion is 2017-06.
What conditions does trial NCT02610868 study?
This clinical trial studies the following conditions: Sialorrhea.
What interventions are being tested in trial NCT02610868?
The interventions under investigation include: MYOBLOC (DRUG).
Who is sponsoring clinical trial NCT02610868?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02610868 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sialorrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02610868's enrollment target sits among peer trials
187 1410th of 2000 higher than 589 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia